fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Submission of phase III study data on pulmonary tuberculosis to the EMA and FDA for Sirturo (bedaquiline) – Janssen Pharma

Written by | 15 Nov 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for the Company’s medicine… read more.

Treating mucus plugs in COPD could affect mortality

Written by | 31 May 2023

Targeting mucus plugs could lower mortality from COPD, chronic obstructive pulmonary disease, the fourth leading cause of death in the United States. Researchers reported this finding on May… read more.

Patients with COPD have higher mortality in year after surgery

Written by | 19 Jan 2023

Patients diagnosed with chronic obstructive pulmonary disease (COPD) who have major surgery have a higher mortality rate in the year after surgery than similar patients who do not… read more.

“Long Covid” linked to disease of small airways in lungs

Written by | 24 Mar 2022

Researchers report that persistent disease of the small airways in the lungs, with yet unknown long-term effects, appears to be a possible log-term effect of COVID-19, and it… read more.

Standard for pulmonary function tests gets an update

Written by | 4 Mar 2022

In the latest update to the pulmonary function tests technical standard series, the American Thoracic Society and European Respiratory Society address the uncertainty around the interpretation of the tests which are essential in determining… read more.

FDA grants Tentative Approval for Yutrepia to treat pulmonary arterial hypertension – Liquidia Corpn

Written by | 26 Jan 2022

Liquidia Corporation has announced that the FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder, previously referred to as LIQ 861. Yutrepia is indicated for the treatment of… read more.

FDA approves Uptravi IV for pulmonary arterial hypertension – J&J

Written by | 19 Aug 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension… read more.

New real-world observational analysis of Uptravi underscores the importance of risk assessment for treating pulmonary arterial hypertension patients -Johnson & Johnson

Written by | 12 Apr 2021

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.